文献速递细胞病理与分子病理

ThyroSeq 在不明确甲状腺病变中的风险分层:细胞病理学关联的单机构经验

Risk stratification of ThyroSeq results in indeterminate thyroid lesions: A single-institution experience of clinicopathologic correlation with cytologic findings.
PubMed 文献 · Cancer Cytopathol · 2024-09-19

该单机构回顾性研究分析了 2017 至 2021 年 520 例意义不明的细胞异型性(AUS)和 111 例滤泡性肿瘤(FN)的甲状腺细针穿刺标本,将 ThyroSeq 结果与细胞形态亚类及手术切除诊断关联。结果显示 AUS 各亚类恶性率不同,细胞异型性亚类最高(16.7%),且中间风险突变者恶性率显著升高(46.7%);结构异型性亚类最低(9.7%),但合并高风险突变时显著升高(62.5%)。结论提示结合细胞亚类、ThyroSeq 风险与分子结果有助于临床管理。

要点

  • AUS 亚类中细胞异型性(III-C)恶性率最高(16.7%),结构异型性(III-A)最低(9.7%)。
  • III-C 中中间风险突变者恶性率达 46.7%,III-A 合并高风险突变者达 62.5%。
  • BRAFV600E 样突变常与 III-C 及经典型甲状腺乳头状癌相关,RAS 样突变在各亚类中最常见。

核心结论

  • AUS 细胞形态亚类具有不同的 ThyroSeq 定义恶性风险和組織学结局,结合亚类、分子风险与结果可优化不明确甲状腺病变的临床管理。

研究设计与样本

  • 单机构回顾性研究,从细胞学数据库检索 2017 至 2021 年 AUS 和 FN 的甲状腺细针穿刺标本,共 520 例 AUS 和 111 例 FN,收集临床信息与 ThyroSeq 结果并与切除诊断关联。

主要发现

  • III-A 合并高风险突变时恶性率显著升高至 62.5%。
  • BRAFV600E 样突变常与 III-C 及经典型甲状腺乳头状癌相关。
  • RAS 样突变是所有亚类中最常见的改变,常与滤泡型病变相关。

关键数值与推荐

  • AUS 亚类分布:细胞异型性(III-C)190 例(36.5%),结构异型性(III-A)109 例(21.0%),细胞及结构异型性(III-CA)138 例(26.5%),嗜酸细胞穿刺(III-O)69 例(13.0%)。

临床怎么用

  • 对 AUS 病变应细分细胞形态亚类,并结合 ThyroSeq 定义的风险及具体分子结果进行临床管理决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: ThyroSeq offers the opportunity to stratify the risk of malignancy (ROM) in the characterization of indeterminate thyroid nodules, especially those categorized as atypia of undetermined significance (AUS). However, whether ThyroSeq interpretations correlate with cytologic features, management, and surgical outcome remains unclear. METHODS: Thyroid fine-needle aspiration specimens categorized as AUS and follicular neoplasm (FN) from 2017 to 2021 were identified from a cytology database search. Patient clinical information and ThyroSeq results were collected and correlated with resection diagnosis if available. RESULTS: A total of 520 cases were classified as AUS and 111 cases were classified as FN. Within the AUS lesions, 190 cases (36.5%) were subcategorized as cytologic atypia (III-C), 109 cases (21.0%) as architectural atypia (III-A), 138 cases (26.5%) as both cytologic and architectural atypia (III-CA), and 69 cases (13.0%) as oncocytic cell aspirate (III-O). Category III-C showed the highest malignancy rate (16.7%; p = .29), and a higher ThyroSeq-defined probability of cancer or noninvasive follicular thyroid neoplasms with papillary-like nuclear features. Notably, within III-C, intermediate-risk mutations led to a significantly higher malignancy rate (46.7%; p = .0012). Conversely, III-A had the lowest malignancy rate (9.7%) but this was significantly increased by concurrent high-risk mutations (62.5%). BRAFV600E-like mutations were frequently associated with III-C and classical papillary thyroid carcinoma in histology. RAS-like mutations were the most common alterations across all subcategories, and were frequently associated with follicular-patterned lesions. CONCLUSIONS: Atypia subcategories have differential ThyroSeq-defined ROMs and histologic outcomes. Combining atypia subcategory interpretation, ThyroSeq-defined ROMs and molecular results aids in optimal clinical management for indeterminate thyroid lesions.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Hsiao WY, Saba NF, Lubin D, et al. Risk stratification of ThyroSeq results in indeterminate thyroid lesions: A single-institution experience of clinicopathologic correlation with cytologic findings. Cancer Cytopathol. 2024. PMID: 39297376. doi:10.1002/cncy.22905

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。